BioSpace News Archive

Diego Pellicer Worldwide, Inc. branded location offers raffle, exclusive deals and more

Cerevel Therapeutics, a biopharmaceutical company focused on developing new medicines to treat disorders of the central nervous system (CNS), today announced the publication of results from a Phase 2a study1 in Neurology demonstrating the anticonvulsant activity of CVL-865 (formerly PF-06372865), a novel α2/3/5-subtype selective GABAA positive allosteric modulator, in patients with photosensitive epilepsy (seizures triggered by visual stimuli).

FHI Clinical manages complex clinical research in resource-limited settings around the world

The researchers have been using Atomwise’s AI-powered in silico screening technology to develop therapeutic treatments for, among others, certain types of strokes, hand-foot-and-mouth disease, and an infection that causes reproductive failure in pigs.

The company is expanding its software-as-a-medical-device platform to support the optimization of ALL diabetes medications.

Savonix announced it has been selected to join StartUp Health’s global network and portfolio of health innovation companies.

The Republic of Armenia Ministry of Health embraces national digital health agenda, partnering with WHISE-Embleema to digitize healthcare data in order to promote science research

Medicine Man Technologies, Inc. (OTCQX: MDCL) (“Medicine Man Technologies” or “Company”), a rapidly growing, vertically integrated cannabis operator, today announced that it will be presenting at the 3rd Annual Benzinga Cannabis Capital Conference, to be held April 17-18, 2019 at the Fairmont Royal York in Toronto, Canada.

Chemistree Technology Inc. (CSE: CHM) (US OTCQB: CHMJF) (the “Company” or “Chemistree”), is pleased to announce the appointment of Mr. Nicholas J. Zitelli to its Board of Directors.

The Mesothelioma Victims Center’s top priority is seeing to it that a Navy Veteran with mesothelioma or asbestos exposure receive the very best possible financial compensation and on an expedited basis if possible.